Abstract
In 2012, Colombia launched human papillomavirus (HPV) vaccination program for girls ages 9 to 12, and in 2013, the target age was expanded to 9 to 17 years. Monitoring the changes of HPV infection prevalence among young women has been proposed as an endpoint for early assessment of HPV vaccination programs. However, the data on HPV prevalence in young ages are very limited. The purpose of this study was to determine the prevalence of HPV infection and the distribution of genotypes in a group of nonvaccinated women ages 18 to 25 years old in three Colombian cities as baseline for the monitoring of the HPV national vaccination program. A total of 1,782 sexually active women were included. Cervical smear samples were collected to perform the Pap smear and HPV DNA detection using a Linear Array HPV assay. Of the 1,782 specimens analyzed, 60.3% were positive for any HPV type; 42.2% were positive for high-risk HPV (HR-HVP) types, and 44.4% for low-risk HPV (LR-HPV) types. Multiple and single infections were identified in 37.1% and 23.2% of samples, respectively. HR-HPV types -16, -52, and -51 were the most predominant with proportions of 11.3%, 7.92%, and 7.9%, correspondingly. The prevalence for HR-HPV 16/18 was 14.4%. HR-HPV prevalence in women with abnormal cytology (75.16%) was higher than in women with normal cytology (38.6%). In conclusion, a high prevalence of HR-HPV was observed among younger women. This HPV type-specific prevalence baseline may be used to monitor postvaccination longitudinal changes and to determine its impact on HPV-related disease incidence in Colombia population. Cancer Prev Res; 11(9); 581-92. ©2018 AACR.
Highlights
Following the establishment of persistent human papillomavirus (HPV) infection as a causal agent of cervical cancer, HPV prophylactic vaccination has been proposed as one of the most important strategies to effectively reduce the burden of this typeNote: Supplementary data for this article are available at Cancer Prevention Research Online.Ó2018 American Association for Cancer Research.of cancer worldwide
Because from the aforementioned 1,782 samples, 122 samples had no cytologic report and one had a cytology interpreted as atypical glandular cells, the analysis for HPV prevalence by cytology was made in only 1,659 samples
In Colombia, the recent introduction of the HPV vaccine program for girls ages up to 17 years represents a new opportunity for the prevention of cervical cancer
Summary
Following the establishment of persistent HPV infection as a causal agent of cervical cancer, HPV prophylactic vaccination has been proposed as one of the most important strategies to effectively reduce the burden of this typeNote: Supplementary data for this article are available at Cancer Prevention Research Online (http://cancerprevres.aacrjournals.org/).Ó2018 American Association for Cancer Research.of cancer worldwide. Aiming at preventing cervical cancer and genital warts, in 2012, quadrivalent HPV vaccination was included in the Colombian National Immunization Program for girls ages 9 to 12 years. In 2013, the target age was expanded to 9 to 17 years old and the original 0-2-6-month immunization schedule was modified to an alternative one of 0-6-60 months. The latter modification was based on www.aacrjournals.org published evidence showing that the immunogenicity of 2-dose prime boost schedule administered with a 6-month interval was not inferior to that observed in the 3 dose prime-prime-boost schedule [12,13,14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
